MiMedx has distributed more than 1 million allografts to date with zero reported adverse reactions attributed to our products.
MiMedx was named #5 on Fortune Magazine’s Top 100 Fastest Growing Companies of 2017.
MiMedx dHACM is the first amnion/chorion dehydrated membrane to be described in a USP monograph.
MiMedx is a leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. “Innovations in Regenerative Medicine” is the framework behind our mission to provide physicians with products and tissues to help the body heal itself.
Today we are a leader in advanced wound care, spine and sports medicine with significant scientific, clinical, operational and commercialization expertise. We intend to leverage these capabilities to remain at the forefront of innovation in regenerative medicine and biopharmaceuticals.
Since our founding, research and development has been the cornerstone of our organization. As a result, we have grown to be a leader in placental based products with over 40 scientific and clinical publications contained in our Compendium, seven completed and published Randomized Controlled Trials (RCTs), and 30 ongoing clinical studies. MiMedx has over 45 placental tissue issued and allowed patents on our products and technologies, with over 90 pending applications.
MiMedx amniotic membrane allografts, processed using the Company’s proprietary PURION® process, utilize terminal sterilization as an essential part of the process. Terminal sterilization provides a greater safety factor than the typical drug or tissue products only processed aseptically.
The proprietary PURION processing technology provides the MiMedx amniotic membrane allografts with their unique capabilities to retain growth factors, provide ease of use by the physician, and offer the capacity to be stored at ambient conditions with a five year shelf life.
MiMedx is a high growth biopharmaceutical company that is unique, as we deliver strong financial performance that will allow us to fuel future growth. Since 2012, MiMedx has been profitable on an Adjusted EBITDA basis. This financial performance allows the company to make investments in areas that build sustainable competitive advantages in our targeted markets while avoiding the dilutive impacts of raising additional capital.